GAMMAGARD LIQUID for
Subcutaneous (SubQ) Administration
Sustained Protection Against Infection1
In the SubQ administration clinical study, 47 patients with PI were given SubQ treatment with GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% Solution. Treatment efficacy was demonstrated with patients treated for a mean of 54 weeks (range 8 to 68 weeks).1
- Low rate of acute serious bacterial infections (less than 1 infection among people taking GAMMAGARD LIQUID for a whole year)
- 3 participants had pneumonia which was treated without hospitalization.
- 0 participants needed to be hospitalized for an infection (or for treatment of an infection)
In a total of 2,294 infusions in the clinical study, the most common side effect for GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% Solution was local infusion site reactions (2.4%).
The most common side effects (seen in ≥5% of patients) were local Infusion site reactions, headache, fatigue, increased heart rate, fever, upper abdominal pain, nausea, vomiting, asthma, increased blood pressure, diarrhea, ear pain, canker sores, migraine, sore throat, and pain in the hands or feet.
Please see below for additional Important Safety Information.
|of infusions were completed without reducing the infusion rate or stopping the infusion due to
side effects or tolerability issues.
GAMMAGARD LIQUID treatment is formulated with1:
- Added Sugars1
- Added Sodium1
- Added Preservatives1
- Stabilized and buffered with glycine1 for those patients in whom additives may be a concern
- The packaging is not made with natural rubber latex1
Reference: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc.